Crinetics | 45.28 +0.49 +1.09% | ||
| CRNX | |||
| 高 46.66 | 开 45.94 | 量 199.68万股 | 总市值 46.42亿 |
| 低 43.94 | 换 1.95% | 额 8966.76万 | 市盈TTM 亏损 |
分时
5日
日K
周K
月K
季K
年K
股事小兵
01-05 22:06
$Crinetics(CRNX)$ 治疗先天性肾上腺增生的二期试验中，PALSONIFY发射执行强劲，并同时降低雄烯二酮和减少糖皮质激素剂量取得积极结果
3讨论 · 1赞
![[大笑]](https://assets.imedao.com/ugc/images/face_regular/v1/emoji_02_laughing.png?v=1 "[大笑]"){kind=small}
@Spica : 3年3倍，重塑内分泌疾病治疗，Crinetics的创新之旅（上） 前言
Crinetics是一家专注于内分泌和代谢疾病领域新药开发的生物科技公司，具有开发FIC药物的能力，核心产品paltusotine用于治疗肢端肥大症和类癌综合征，口服小分子疗效可比注射类药物。近3年公司股价上涨3倍。![[围观]](https://assets.imedao.com/ugc/images/face/emoji_32_onlook.png?v=1 "[围观]")
公司概况
Crinetics Pharmaceuticals于2008年成立，总部位...
Crinetics是一家专注于内分泌和代谢疾病领域新药开发的生物科技公司，具有开发FIC药物的能力，核心产品paltusotine用于治疗肢端肥大症和类癌综合征，口服小分子疗效可比注射类药物。近3年公司股价上涨3倍。
公司概况
Crinetics Pharmaceuticals于2008年成立，总部位...
2赞
股事小兵
01-07 23:09
$Crinetics(CRNX)$ 前几天没赚到 现在买入52.3
1赞
Crinetics(CRNX)
2025-12-19 07:55
$Crinetics(CRNX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-058056 Size: 13 KB 网页链接
Crinetics(CRNX)
01-08 05:05
$Crinetics(CRNX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-26-006276 Act: 33 Size: 671 KB 网页链接
Crinetics(CRNX)
2025-12-30 05:46
$Crinetics(CRNX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-059009 Size: 6 KB 网页链接
Crinetics(CRNX)
2025-12-04 05:35
$Crinetics(CRNX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-055054 Size: 9 KB 网页链接
Crinetics(CRNX)
01-08 05:45
$Crinetics(CRNX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-26-006421 Act: 34 Size: 477 KB 网页链接
Crinetics(CRNX)
01-08 06:15
$Crinetics(CRNX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-26-001230 Size: 8 KB 网页链接
Crinetics(CRNX)
01-06 05:25
$Crinetics(CRNX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-26-002458 Act: 33 Size: 526 KB 网页链接
Crinetics(CRNX)
2025-12-02 05:45
$Crinetics(CRNX)$ 144 Report of proposed sale of securities Accession Number: 0001950047-25-009572 Act: 33 Size: 6 KB 网页链接
Crinetics(CRNX)
01-26 22:15
$Crinetics(CRNX)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001658247-26-000003 Act: 34 Size: 139 KB 网页链接
Crinetics(CRNX)
02-03 05:35
$Crinetics(CRNX)$ 144 Report of proposed sale of securities Accession Number: 0001950047-26-000824 Act: 33 Size: 7 KB 网页链接
Crinetics(CRNX)
2025-12-18 06:05
$Crinetics(CRNX)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001658247-25-000022 Act: 34 Size: 337 KB 网页链接
Crinetics(CRNX)
2025-11-12 22:35
$Crinetics(CRNX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000902219-25-000398 Act: 34 Size: 17 KB 网页链接
Crinetics(CRNX)
昨天03:55
$Crinetics(CRNX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000908834-26-000040 Act: 34 Size: 62 KB 网页链接
Crinetics(CRNX)
01-06 05:05
$Crinetics(CRNX)$ 8-K Current report, items 2.02, 7.01, 8.01, and 9.01 Accession Number: 0001193125-26-002368 Act: 34 Size: 12 MB 网页链接
Crinetics(CRNX)
01-06 05:45
$Crinetics(CRNX)$ 144 Report of proposed sale of securities Accession Number: 0001950047-26-000146 Act: 33 Size: 4 KB 网页链接
Crinetics(CRNX)
01-03 05:35
$Crinetics(CRNX)$ 144 Report of proposed sale of securities Accession Number: 0001950047-26-000066 Act: 33 Size: 6 KB 网页链接
Crinetics(CRNX)
01-14 06:05
$Crinetics(CRNX)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001193125-26-011872 Act: 34 Size: 6 MB 网页链接